Perceptive Advisors KOD Position
Active7-Fund ConvergencePerceptive Advisors increased their position in Kodiak Sciences Inc. (KOD) in Q4 2025, holding $23.7M worth of shares across 848,900 shares.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
KOD is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Tarcocimab tedromer in 137 days (Aug 31, 2026), making the timing of Perceptive's position particularly relevant.
Short interest stands at 17.3% of float with 11.6 days to cover, indicating significant bearish positioning against Perceptive's long thesis.
About Kodiak Sciences Inc.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Full company profile →Short Interest
17.3%
11.6 days to cover
Perceptive Advisors KOD Position History
Frequently Asked Questions
Does Perceptive Advisors own KOD?
Yes. As of Q4 2025, Perceptive Advisors holds 848,900 shares of Kodiak Sciences Inc. (KOD) valued at $23.7M. This data comes from their SEC 13F filing.
How many hedge funds own KOD?
7 specialist biotech hedge funds currently hold KOD, including Baker Bros. Advisors, RTW Investments, Driehaus Capital and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Perceptive Advisors first buy KOD?
Perceptive Advisors's position in KOD was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's KOD position increasing or decreasing?
Perceptive Advisors increased their KOD position in the most recent quarter, adding 214,323 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
KODCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →